Skip Navigation



JAC Advance Access published online on September 1, 2003
Journal of Antimicrobial Chemotherapy, doi:10.1093/jac/dkg399
© 2003 by The British Society for Antimicrobial Chemotherapy
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
52/4/683    most recent
dkg399v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Datta, K.
Right arrow Articles by Banerjee, U.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Datta, K.
Right arrow Articles by Banerjee, U.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2003 The British Society for Antimicrobial Chemotherapy

Brief report

Fluconazole and itraconazole susceptibility of clinical isolates of Cryptococcus neoformans at a tertiary care centre in India: a need for care

K. Datta 1 , N. Jain 2 , S. Sethi 2 , A. Rattan 3 , A. Casadevall 4 , and U. Banerjee 2

1 Department of Microbiology, All India Institute of Medical Sciences, New Delhi 110029; Microbiology NDDR, Ranbaxy Research Laboratories, Gurgaon 122001, Haryana, India
2 Department of Microbiology, All India Institute of Medical Sciences, New Delhi 110029
3 Microbiology NDDR, Ranbaxy Research Laboratories, Gurgaon 122001, Haryana, India
4 Department of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, NY 10461, USA

Received 3 October 2002 ; revised 30 June 2003 ; accepted 2 July 2003

Abstract

Objectives: In cryptococcosis, fluconazole is a standard prophylactic, therapeutic and maintenance option, particularly in the expanding HIV/AIDS group. However, its excessive use may lead to resistance in Cryptococcus neoformans. Variations in clinical response to fluconazole have already been noted elsewhere, and cases of post-therapy relapse are not uncommon. To assess azole antifungal susceptibility profiles of clinical cryptococcal isolates in India, the All India Institute of Medical Sciences (AIIMS) has recently initiated preliminary studies using NCCLS M27-A.

Materials and methods: Twenty-eight randomly chosen AIIMS clinical isolates (spanning 1997-2000), 16 isolates from other institutions in North India, and six reference strains of C. neoformans were subjected to susceptibility testing to fluconazole and itraconazole.

Results: Among clinical isolates, susceptibilities to fluconazole and itraconazole were 84.1% and 93.2%, respectively. MICs for all clinical isolates were 0.25-32 mg/L for fluconazole and <0.03-0.25 mg/L for itraconazole. MIC50 and MIC90 values for fluconazole were 4 and 16 mg/L, respectively, and those for itraconazole were 0.032 and 0.125 mg/L, respectively. Out of 28 AIIMS clinical isolates, 22 had minimum fungicidal concentrations (MFCs) of fluconazole at ³128 mg/L. Moderately high fluconazole MICs (16-32 mg/L) were observed in 16% of clinical isolates--probably the first such report from India. MIC/MFC ratios for fluconazole and itraconazole were 1:32 or more in 16 AIIMS clinical isolates, indicating possible azole tolerance. There was good agreement between MIC values obtained by the micro- and macro-broth dilution techniques of M27-A compared in this study.

Conclusions: The observed MIC data warrant continued surveillance of susceptibility values of clinical cryptococcal isolates in India.

Keywords: cryptococcosis, MICs, azole antifungals, clinical isolates, India
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J. Clin. Microbiol.Home page
M. A. Pfaller, D. J. Diekema, D. L. Gibbs, V. A. Newell, H. Bijie, D. Dzierzanowska, N. N. Klimko, V. Letscher-Bru, M. Lisalova, K. Muehlethaler, et al.
Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2007: 10.5-Year Analysis of Susceptibilities of Noncandidal Yeast Species to Fluconazole and Voriconazole Determined by CLSI Standardized Disk Diffusion Testing
J. Clin. Microbiol., January 1, 2009; 47(1): 117 - 123.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
Z. U. Khan, H. S. Randhawa, T. Kowshik, A. Chowdhary, and R. Chandy
Antifungal susceptibility of Cryptococcus neoformans and Cryptococcus gattii isolates from decayed wood of trunk hollows of Ficus religiosa and Syzygium cumini trees in north-western India
J. Antimicrob. Chemother., August 1, 2007; 60(2): 312 - 316.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Microbiol.Home page
M. A. Pfaller, L. Boyken, S. A. Messer, S. Tendolkar, R. J. Hollis, and D. J. Diekema
Comparison of Results of Voriconazole Disk Diffusion Testing for Candida Species with Results from a Central Reference Laboratory in the ARTEMIS Global Antifungal Surveillance Program
J. Clin. Microbiol., October 1, 2005; 43(10): 5208 - 5213.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Microbiol.Home page
M. A. Pfaller, S. A. Messer, L. Boyken, C. Rice, S. Tendolkar, R. J. Hollis, G. V. Doern, and D. J. Diekema
Global Trends in the Antifungal Susceptibility of Cryptococcus neoformans (1990 to 2004)
J. Clin. Microbiol., May 1, 2005; 43(5): 2163 - 2167.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.